These studies underline the important role of inflammation in the HL tumor microenvironment in the response(s) to therapy, which includes the CD28 expression on TILs, the CD80/CD86 level, the PD-L2 expression, and the stage of JAK/STAT signaling in HRS, among others. The gene discussed is CD86; the disease is neoplasm.